These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 25182505

  • 1. Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice.
    Nieuwenhuizen L, Roosendaal G, Mastbergen SC, Coeleveld K, Biesma DH, Lafeber FP, Schutgens RE.
    Thromb Haemost; 2014 Nov; 112(5):1044-50. PubMed ID: 25182505
    [Abstract] [Full Text] [Related]

  • 2. On-demand treatment with the iron chelator deferasirox is ineffective in preventing blood-induced joint damage in haemophilic mice.
    Pulles AE, van Vulpen LFD, Coeleveld K, Mastbergen SC, Schutgens REG, Lafeber FPJG.
    Haemophilia; 2021 Jul; 27(4):648-656. PubMed ID: 34043875
    [Abstract] [Full Text] [Related]

  • 3. Haemophilic arthropathy: the usefulness of intra-articular oxytetracycline (synoviorthesis) in the treatment of chronic synovitis in children.
    Bernal-Lagunas R, Aguilera-Soriano JL, Berges-Garcia A, Luna-Pizarro D, Perez-Hernandez E.
    Haemophilia; 2011 Mar; 17(2):296-9. PubMed ID: 21070486
    [Abstract] [Full Text] [Related]

  • 4. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes.
    Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA.
    Haemophilia; 2008 Jul; 14(4):804-9. PubMed ID: 18422608
    [Abstract] [Full Text] [Related]

  • 5. Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage.
    Valentino LA, Hakobyan N, Rodriguez N, Hoots WK.
    Haemophilia; 2007 Nov; 13 Suppl 3():10-3. PubMed ID: 17822515
    [Abstract] [Full Text] [Related]

  • 6. Silencing of protease-activated receptors attenuates synovitis and cartilage damage following a joint bleed in haemophilic mice.
    Nieuwenhuizen L, Schutgens RE, Coeleveld K, Mastbergen SC, Schiffelers RM, Roosendaal G, Biesma DH, Lafeber FP.
    Haemophilia; 2016 Jan; 22(1):152-9. PubMed ID: 26189554
    [Abstract] [Full Text] [Related]

  • 7. Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice.
    Nieuwenhuizen L, Roosendaal G, Mastbergen SC, Coeleveld K, Biesma DH, Lafeber FP, Schutgens RE.
    J Thromb Haemost; 2014 Feb; 12(2):237-45. PubMed ID: 24283895
    [Abstract] [Full Text] [Related]

  • 8. Haemarthrosis stimulates the synovial fibrinolytic system in haemophilic mice.
    Nieuwenhuizen L, Roosendaal G, Coeleveld K, Lubberts E, Biesma DH, Lafeber FP, Schutgens RE.
    Thromb Haemost; 2013 Jul; 110(1):173-83. PubMed ID: 23677440
    [Abstract] [Full Text] [Related]

  • 9. Orthopaedic management of haemophilia arthropathy of the ankle.
    Pasta G, Forsyth A, Merchan CR, Mortazavi SM, Silva M, Mulder K, Mancuso E, Perfetto O, Heim M, Caviglia H, Solimeno L.
    Haemophilia; 2008 Jul; 14 Suppl 3():170-6. PubMed ID: 18510538
    [Abstract] [Full Text] [Related]

  • 10. Haemophilic synovitis: basic concepts.
    Rodriguez-Merchan EC.
    Haemophilia; 2007 Nov; 13 Suppl 3():1-3. PubMed ID: 17822513
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors.
    Chueh HW, Sung KW, Lee SH, Yoo KH, Koo HH, Kim JY, Cho EJ.
    Pediatr Blood Cancer; 2012 Mar; 58(3):441-7. PubMed ID: 21638755
    [Abstract] [Full Text] [Related]

  • 14. Rofecoxib as adjunctive therapy for haemophilic arthropathy.
    Rattray B, Nugent DJ, Young G.
    Haemophilia; 2005 May; 11(3):240-4. PubMed ID: 15876269
    [Abstract] [Full Text] [Related]

  • 15. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW.
    Acta Haematol; 2013 May; 129(2):72-7. PubMed ID: 23154600
    [Abstract] [Full Text] [Related]

  • 16. Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
    Ktena YP, Athanasiadou A, Lambrou G, Adamaki M, Moschovi M.
    J Pediatr Hematol Oncol; 2013 Aug; 35(6):447-50. PubMed ID: 23669734
    [Abstract] [Full Text] [Related]

  • 17. Effect of radiosynoviorthesis on the progression of arthropathy and haemarthrosis reduction in haemophilic patients.
    Querol-Giner M, Pérez-Alenda S, Aguilar-Rodríguez M, Carrasco JJ, Bonanad S, Querol F.
    Haemophilia; 2017 Nov; 23(6):e497-e503. PubMed ID: 28891593
    [Abstract] [Full Text] [Related]

  • 18. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency.
    Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA.
    Haemophilia; 2004 May; 10(3):280-7. PubMed ID: 15086328
    [Abstract] [Full Text] [Related]

  • 19. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J, Jonasova A, Vondrakova J, Cervinek L, Belohlavkova P, Neuwirtova R.
    Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.